Back to Search Start Over

Identification of altered miRNAs and their targets in placenta accreta.

Authors :
Murrieta-Coxca JM
Barth E
Fuentes-Zacarias P
Gutiérrez-Samudio RN
Groten T
Gellhaus A
Köninger A
Marz M
Markert UR
Morales-Prieto DM
Source :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Mar 03; Vol. 14, pp. 1021640. Date of Electronic Publication: 2023 Mar 03 (Print Publication: 2023).
Publication Year :
2023

Abstract

Placenta accreta spectrum (PAS) is one of the major causes of maternal morbidity and mortality worldwide with increasing incidence. PAS refers to a group of pathological conditions ranging from the abnormal attachment of the placenta to the uterus wall to its perforation and, in extreme cases, invasion into surrounding organs. Among them, placenta accreta is characterized by a direct adhesion of the villi to the myometrium without invasion and remains the most common diagnosis of PAS. Here, we identify the potential regulatory miRNA and target networks contributing to placenta accreta development. Using small RNA-Seq followed by RT-PCR confirmation, altered miRNA expression, including that of members of placenta-specific miRNA clusters (e.g., C19MC and C14MC), was identified in placenta accreta samples compared to normal placental tissues. In situ hybridization (ISH) revealed expression of altered miRNAs mostly in trophoblast but also in endothelial cells and this profile was similar among all evaluated degrees of PAS. Kyoto encyclopedia of genes and genomes (KEGG) analyses showed enriched pathways dysregulated in PAS associated with cell cycle regulation, inflammation, and invasion. mRNAs of genes associated with cell cycle and inflammation were downregulated in PAS. At the protein level, NF-κB was upregulated while PTEN was downregulated in placenta accreta tissue. The identified miRNAs and their targets are associated with signaling pathways relevant to controlling trophoblast function. Therefore, this study provides miRNA:mRNA associations that could be useful for understanding PAS onset and progression.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Murrieta-Coxca, Barth, Fuentes-Zacarias, Gutiérrez-Samudio, Groten, Gellhaus, Köninger, Marz, Markert and Morales-Prieto.)

Details

Language :
English
ISSN :
1664-2392
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in endocrinology
Publication Type :
Academic Journal
Accession number :
36936174
Full Text :
https://doi.org/10.3389/fendo.2023.1021640